Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

FOSTER CITY, CA – June 23, 2020 (GLOBE NEWSWIRE) — Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that the results of a Stanford study using its drug sensitivity screening platform have been published in Blood Advances (June 23, 2020; Volume 4, Issue 12).

Learn More
Notable’s The ANSWer Study

Notable’s The ANSWer Study

Notable’s The ANSWer Study: An Observational Clinical Trial for Patients with Blood Cancer by Susanna Wen MsM (Master of Medicine), Ph.D Notable’s first self-sponsored clinical trial to validate cancer patient matching on its automated high-throughput scientific technology platform At Notable, we are aiming to redefine cancer treatment with the development of a functional precision medicine […]

Learn More
×